Trial · NCT07471516
Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia
NCT07471516, Phase 1, Phase 2, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia. Trials, record NCT07471516. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07471516
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia
- NCT number
- NCT07471516
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 2 participants, estimated
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Conditions
- Congenital Dyserythropoietic Anemia (CDA)
- Interventions
- zoledronic acid
- First posted
- 2026-03-13
- Last updated
- 2026-03-13
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Hemoglobin Level From Baseline | 12 weeks after the first dose | The primary endpoint is the hematologic response achieved by participants at 12 weeks after the first dose of Zoledronic acid. Response includes: 1) Complete Response (CR): Hemoglobin ≥ 120 g/L; 2) Partial Response (PR): Not meeting CR criteria, but achieving independence from red blood cell transfusions OR an increase in HGB of ≥ 20 g/L from baseline. |
| Secondary | Change in Hemoglobin Level at 4 Weeks | 4 weeks after the first dose | Assessment of the increase in peripheral blood hemoglobin concentration from baseline to 4 weeks after the first dose |
| Secondary | Change in Red Blood Cell Transfusion Interval | Up to 24 weeks | Comparison of the time interval between red blood cell transfusions before and after Zoledronic acid treatment |
| Secondary | Change in Spleen Size | Up to 24 weeks | Assessment of the change in spleen size measured by ultrasound compared to baseline |
| Secondary | Change in Quality of Life Assessed by the 36-Item Short Form Health Survey (SF-36) | Up to 24 weeks | Assessment of the change in patient quality of life compared to baseline. It is measured using the 36-Item Short Form Health Survey (SF-36). The score ranges from 0 to 100, where a higher score indicates a better quality of life. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07471516
GET https://conductscience.org/api/trials/v1/NCT07471516/registered